Related Experiment Video
Updated: Apr 1, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?
Mireia Pelegrin1, Mar Naranjo-Gomez1, Marc Piechaczyk1
1Equipe Labellisée par la Ligue contre le Cancer - Institut de Génétique Moléculaire de Montpellier, UMR 5535 CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, Université de Montpellier, 163 rue Auguste Broussonnet, 34090 Montpellier, France.
Abstract:
Monoclonal antibodies (mAbs) are increasingly being considered as agents to fight severe viral diseases. So far, they have essentially been selected and used on the basis of their virus-neutralizing activity and/or cell-killing activity to blunt viral propagation via direct mechanisms. There is, however, accumulating evidence that they can also induce long-lasting protective antiviral immunity by recruiting the endogenous immune system of infected individuals during the period of immunotherapy. Exploiting this property may revolutionize antiviral mAb-based immunotherapies, with benefits for both patients and healthcare systems.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Affinity and Avidity
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Subviral Agents

